Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Coagulation Disorders in Infective Endocarditis: Role of Pathogens, Biomarkers, Antithrombotic Therapy (Systematic Review)

https://doi.org/10.20996/1819-6446-2022-06-14

Full Text:

Abstract

The issue of antithrombotic therapy in patients with infective endocarditis has been studied for over 75 years. During that time studying of pathogenesis of the disease and its embolic complications, lead to the introduction of the concept of “immunothrombosis”. That mechanism allows infective agents (mostly bacteria) to be cloaked from the immune system and to multiply freely, leading to growth of vegetation, thus resulting in higher chance of fragmentation. Small-scale experimental and clinical studies on the correction of hemostatic disorders in infective endocarditis, that were performed in 20th century, didn’t show any significant results, that could affect clinical practice. However, reinterpretation of available data on coagulative system will allow to have elements of hemostasis as an application point in treating infective endocarditis. The article will discuss latest insights on the role of hemostasis system in pathophysisology of infective endocarditis, its effects on the development of the embolic complications, perspectives for diagnostics and treatment.

About the Authors

A. S. Pisaryuk
RUDN University; Moscow City Hospital named after V.V. Vinogradov
Russian Federation

Alexandra S. Pisaryuk - eLibrary SPIN5602-1059.

Moscow



V. A. Zamarashkina
RUDN University
Russian Federation

Veronika A. Zamarashkina - eLibrary SPIN 4956-6744.

Moscow



N. B. Safarova
Lomonosov Moscow State University
Russian Federation

Nargiz B. Safarova - eLibrary SPIN 9692-2329



N. M. Povalyaev
RUDN University
Russian Federation

Nikita M. Povalyaev - eLibrary SPIN 7336-6461.

Moscow



E. O. Kotova
RUDN University
Russian Federation

Elizaveta O. Kotova - eLibrary SPIN 6397-6480.

Moscow



U. I. Babukhina
A.N. Bakulev Research Center for Cardiovascular Surgery
Russian Federation

Julia I. Babukhina - eLibrary SPIN 2000-2010.

Moscow



E. M. Koltsova
Center for Theoretical Problems of Physicochemical Pharmacology; Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation

EkaterinaM. Koltsova - eLibrary SPIN 1902-3431.

Moscow



Zh. D. Kobalava
RUDN University
Russian Federation

Zhanna D. Kobalava - eLibrary SPIN 9828-5409.

Moscow



References

1. Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222-3232. DOI:10.1093/eurheartj/ehz620.

2. Marques A, Cruz I, Caldeira D, et al. Risk factors for in-hospital mortality in infective endocarditis. Arq Bras Cardiol. 2020;114(1):1-8. DOI:10.36660/abc.20180194.

3. Moiseev VS, Kobalava ZD, Pisaryuk AS, et al. Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience). Kardiologiia. 2018;58(12):66-75 (In Russ.) DOI:10.18087/cardio.2018.12.10192.

4. Russian statistical yearbook. Moscow: Rosstat; 2021 [cited 2022 Jan 09]. Available from: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf (In Russ.)

5. Infective endocarditis and infection of intracardiac devices. Clinical guidelines (2021) [cited 2022 Jan 09]. Available from: https://scardio.ru/content/Guidelines/2020/KP_Inf_Endokardit-unlocked.pdf (In Russ.)

6. Lichtman S. Treatment of subacute bacterial endocarditis: current results. Ann Intern Med. 1943;19(5):787. DOI:10.7326/0003-4819-19-5-787.

7. Pisaryuk AS, Kotova EO, Karaulova YuL, Milto AS. History of the study of infective endocarditis. Clinical Pharmacology and Therapy. 2018;(2):77-84 (In Russ.)

8. Durante-Mangoni E, Molaro R, Iossa D. The Role of Hemostasis in Infective Endocarditis. Curr Infect Dis Rep. 2014;16(11):1-9. DOI:10.1007/s11908-014-0435-8.

9. Bancsi M, Veltrop M, Bertina RM, Thompson J. Role of phagocytosis in activation of the coagulation system in Streptococcus sanguis endocarditis. Infect Immun. 1996;64(12):5166-70. DOI:10.1128/iai.64.12.5166-5170.1996.

10. Durante-Mangoni E, Iossa D, Molaro R, et al. Prevalence and significance of two major inherited thrombophilias in infective endocarditis. Intern Emerg Med. 2015;10(5):587-94. DOI:10.1007/s11739-015-1214-8.

11. Gafter-Gvili A, Mansur N, Bivas A, et al. Thrombocytopenia in Staphylococcus aureus bacteremia: Risk factors and prognostic importance. Mayo Clin Proc. 2011;86(5):389-96. DOI:10.4065/mcp.2010.0705.

12. Icli A, Tayyar S, Varol E, et al. Mean platelet volume is increased in infective endocarditis and decreases after treatment. Med Princ Pract. 2013;22(3):270-3. DOI:10.1159/000345393.

13. Kolesnikova NV, Samoylenko ES. The role of cytokines in the pathogenesis of infective endocarditis. Immunologiya. 2020;41(3):262-8 (In Russ.) DOI:10.33029/0206-4952-2020-41-3-262-268.

14. Liesenborghs L, Meyers S, Vanassche T, Verhamme P. Coagulation: At the heart of infective endocarditis. J Thromb Haemost. 2020;18(5):995-1008. DOI:10.1111/jth.14736.

15. Maltseva NV, Laputenko TA, Smirnova AS, Kan SL. Polymorphism and synergism of the hemostasis system genes in pathogenesis of infective endocarditis. Mol Meditsina (Molecular Med). 2019;17(4):45-51 (In Russ.) DOI:10.29296/24999490-2019-04-07.

16. Sy RW, Chawantanpipat C, Richmond DR, Kritharides L. Thrombocytopenia and Mortality in Infective Endocarditis. J Am Coll Cardiol. 2008;51(18):1824-25. DOI:10.1016/j.jacc.2008.01.034.

17. Chapaeva NN, Bakharev YuS, Seryapin YuV, et al. The role of hemostasis genes polymorphism in the diagnosis of thromboembolic complications in nonbacterial thrombotic endocarditis. Journal of Siberian Medical Sciences. 2013;(4):59 (In Russ.) DOI:10.1017/CBO9781107415324.004.

18. Chambers ST, Murdoch DR, Morris A, et al. HACEK Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort. PLoS One. 2013;8(5):e63181. DOI:10.1371/journal.pone.0063181.

19. Nomura R, Otsugu M, Naka S, et al. Contribution of the interaction of Streptococcus mutans serotype k strains with fibrinogen to the pathogenicity of infective endocarditis. Infect Immun. 2014;82(12): 5223-34. DOI:10.1128/IAI.02164-14.

20. Jung CJ, Yeh CY, Hsu R Bin, et al. Endocarditis pathogen promotes vegetation formation by inducing intravascular neutrophil extracellular traps through activated platelets. Circulation. 2015; 131(6):571-81. DOI:10.1161/CIRCULATIONAHA.114.011432.

21. Gragnano F, Crisci M, Bigazzi MC, et al. Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. Angiology. 2018;69(2):103-12. DOI:10.1177/0003319717708070.

22. Liesenborghs L, Verhamme P, Vanassche T. Staphylococcus aureus, master manipulator of the human hemostatic system. J Thromb Haemost. 2018;16(3):441-54. DOI:10.1111/jth.13928.

23. Sullam PM, Bayer AS, Foss WM, Cheung AL. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun. 1996;64(12):4915-21. DOI:10.1128/iai.64.12.4915-4921.1996.

24. Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Staphylococcus aureus mediate activation of human platelets via fibrinogen and fibronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcγRIIa receptor. Mol Microbiol. 2006;59(1):212-30. DOI:10.1111/j.13652958.2005.04922.x.

25. Kupferwasser LI, Yeaman MR, Shapiro SM, et al. In vitro susceptibility to thrombin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental staphylococcus aureus endocarditis microbiological, histopathologic, and echocardiographic anal. Circulation. 2002;105(6):746-52. DOI:10.1161/hc0602.103721.

26. Forsblom E, Lepäntalo A, Wartiovaara-Kautto U, et al. Changes in hemostasis parameters in nonfatal methicillin-sensitive Staphylococcus aureus bacteremia complicated by endocarditis or thromboembolic events: a prospective gender-age adjusted cohort study. APMIS. 2019;127(7):515-28. DOI:10.1111/apm.12955.

27. Demirbag R. Using the D-dimer test in infective endocarditis. Turk Kardiyol Dern Arsivi-Archives Turkish Soc Cardiol. 2013;41(7):595-7. DOI:10.5543/tkda.2013.09483.

28. Buyukasýk NS, Ileri M, Alper A, et al. Increased Blood Coagulation and Platelet Activation in Patients with Infective Endocarditis and Embolic Events. Clin Cardiol. 2004;27(3):154-8. DOI:10.1002/clc.4960270312.

29. Snipsøyr MG, Ludvigsen M, Petersen E, et al. A systematic review of biomarkers in the diagnosis of infective endocarditis. Int J Cardiol. 2016;202:564-70. DOI:10.1016/j.ijcard.2015.09.028.

30. Vinogradova TL, Chipigina NS, Ozeretsky KS, et al. Thromboembolic complications in subacute infective endocarditis. Vestnik RGMU. 2005;8(47):48-54 (In Russ.)

31. Vinogradova Т, Chipigina N, Ozeretsky K, Petukhov E. Thromboembolic syndrome and systemic hemostasis in subacute infective endocarditis. Vrach. 2005;(5):22-4 (In Russ.)

32. Habib G. Management of infective endocarditis. Heart. 2006;92(1):124-30. DOI:10.1136/hrt. 2005.063719.

33. Taranova MV, Androsova TV, Kozlovskaya LV, et al. The prognostic value of thromboembolic complications in infective endocarditis, the possibility of prevention. Klinicheskaja Medicina. 2018;96(2):129-36 (In Russ.)

34. Hubert S, Thuny F, Resseguier N, et al. Prediction of symptomatic embolism in infective endocarditis: Construction and validation of a risk calculator in a multicenter cohort. J Am Coll Cardiol. 2013;62(15):1384-92. DOI:10.1016/j.jacc.2013.07.029.

35. Rizzi M, Ravasio V, Carobbio A, et al. Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). BMC Infect Dis. 2014;14(1):230. DOI:10.1186/1471-2334-14-230.

36. Hook EW, Sande MA. Role of the vegetation in experimental Streptococcus viridans endocarditis. Infect Immun. 1974;10(6):1433-8. DOI:10.1128/iai.10.6.1433-1438.1974.

37. Levison ME, Carrizosa J, Tanphaichitra D, et al. Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. Blood. 1977;49(4):645-50. DOI:10.1182/blood.v49.4.645.645.

38. Thorig L, Thompson J, Eulderink F. Effect of warfarin on the induction and course of experimental Staphylococcus epidermis endocarditis. Infect Immun. 1977;17(3):504-9. DOI:10.1128/iai.17.3.504-509.1977.

39. Johnson CE, Dewar HA. Effect of sulphinpyrazone on the development of experimental endocardial vegetations. Cardiovasc Res. 1982;16(11):657-62. DOI:10.1093/cvr/16.11.657.

40. Pujadas R, Escrivá E, Fernández F, et al. [Effect of various doses of aspirin on the development of aseptic thrombotic aortic endocarditis experimentally induced in the rabbit]. Rev Esp Cardiol. 1988;41(1):31-4 (In Spanish).

41. Nicolau DP, Freeman CD, Nightingale CH, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun. 1993;61(4):1593-5. DOI:10.1128/iai.61.4. 1593-1595.1993.

42. Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1995;39(8):1748-51. DOI:10.1128/AAC.39.8.1748.

43. Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1998;9(4):2279. DOI:10.1016/S0924-8579(97)00056-3.

44. Nicolau DP, Tessier A PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1999;11(2):159-61. DOI:10.1016/S0924-8579(98)00092-2.

45. Kupferwasser LI, Yeaman MR, Shapiro SM et al. Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects. Circulation. 1999;99(21):2791-7. DOI:10.1161/01.CIR.99.21.2791.

46. Veloso TR, Que YA, Chaouch A, et al. Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: A role for long-term prevention of infective endocarditis in humans? J Infect Dis. 2015;211(1):72-9. DOI:10.1093/infdis/jiu426.

47. Hannachi N, Ogé-Ganaye E, Baudoin JP, et al. Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. Front Pharmacol. 2020;11:863. DOI:10.3389/fphar.2020.00863.

48. Katz LN, Elek SR. Combined heparin and chemotherapy in subacute bacterial endocarditis. J Am Med Assoc. 1944;124(3):149-52. DOI:10.1001/jama.1944.02850030017004.

49. Loewe L, Rosenblatt P, Greene HJ. Combined penicillin and heparin therapy of subacute bacterial endocarditis. JAMA. 1944;124(3):144-9. DOI:10.1001/jama.1944.02850030012003.

50. Priest WS, Smith JM, McGee CJ. The Effect of Anticoagulants on the Penicillin Therapy and the Pathologic Lesion of Subacute Bacterial Endocarditis. N Engl J Med. 1946;235(20):699-706. DOI:10.1056/NEJM194611142352001.

51. Thill CJ, Meyer OO. Experiences with penicillin and dicumarol in the treatment of subacute bacterial endocarditis. Am J Med Sci. 1947;213(3):300-7. DOI:10.1097/00000441-194703000-00005.

52. Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation. 1978;57(5):1004-7. DOI:10. 1161/01.CIR.57.5.1004.

53. Paschalisa C, Pugsley W, John R, Harrison MJG. Rate of cerebral embolic events in relation to antibiotic and anticoagulant therapy in patients with bacterial endocarditis. Eur Neurol. 1990;30(2):87-9. DOI:10.1159/000117317.

54. Taha TH, Durrant SS, Mazeika PK, et al. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med. 1992;231(5):543-6. DOI:10.1111/j.1365-2796.1992.tb00971.x.

55. Demin AA, Drobysheva VP, Mil'to A.S, et al. Infective endocarditis: antiplatelet agents in the treatment of hemostasis disorders. Clinical Pharmacology and Therapy. 1995;(1):51-2 (In Russ.)

56. Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2003;42(5):775-80. DOI:10.1016/S07351097(03)00829-5.

57. Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis. 2007;44(9):1180-6. DOI:10.1086/513197.

58. Chan KL, Tam J, Dumesnil JG, et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis. 2008;46(1):85-92. DOI:10.1086/524021.

59. Pepin J, Tremblay V, Bechard D, et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15(2):193-9. DOI:10.1111/j.1469-0691.2008.02665.x.

60. Eisen DP, Corey GR, McBryde ES, et al. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect. 2009;58(5):3328. DOI:10.1016/j.jinf.2009.03.006.

61. Snygg-Martin U, Rasmussen R V, Hassager C, et al. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. Eur J Clin Microbiol Infect Dis. 2011;30(2):1517. DOI:10.1007/s10096-010-1063-3.

62. Habib A, Irfan M, Baddour LM, et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace. 2013;15(2):227-35. DOI:10.1093/europace/eus292.

63. Ong E, Mechtouff L, Bernard E, et al. Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature. J Neurol. 2013;260(5):1339-42. DOI:10.1007/s00415012-6802-1.

64. Eisen DP, Mcbryde ES. An association between aspirin use in human cases of infective endocarditis and reduced systemic embolism is shown in meta-analysis of observational studies. J Infect Dis Adv Access. 2015;212(4):673-4. DOI:10.1093/infdis/jiv131.

65. Pathickal SM, Park TE, Sharma R. Clinical Outcomes Associated With the Use of Anticoagulant and Antiplatelet Agents in Patients Undergoing Treatment for Infective Endocarditis: A Pilot Study. Clin Ther. 2020;42(9):1828-38. DOI:10.1016/j.clinthera.2020.07.007.

66. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-128. DOI:10.1093/eurheartj/ehv319.

67. Preston AH, Williams S, Archer J. A review of the role of anticoagulation for patients with infective endocarditis and embolic stroke. Clin Case Reports. 2016;4(5):513-6. DOI:10.1002/ccr3.556.

68. Sloane KL, Raymond SB, Rabinov JD, Singhal AB. Mechanical Thrombectomy in Stroke from Infective Endocarditis: Case Report and Review. J Stroke Cerebrovasc Dis. 2020;29(1):104501. DOI:10.1016/j.jstrokecerebrovasdis.2019.104501.

69. Lacey MJ, Raza S, Rehman H, et al. Coronary Embolism: A Systematic Review. Cardiovasc Revascularization Med. 2020;21(3):367-74. DOI:10.1016/j.carrev.2019.05.012.

70. Leeten K, Jacques N, Lancellotti P, Oury C. Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand? Front Cell Dev Biol. 2021;9:716302. DOI:10.3389/fcell.2021.716302.

71. Vanassche T, Peetermans WE, Herregods MC, et al. Anti-thrombotic therapy in infective endocarditis. Expert Rev Cardiovasc Ther. 2011;9(9):1203-19. DOI:10.1586/erc.11.100.


Review

For citations:


Pisaryuk A.S., Zamarashkina V.A., Safarova N.B., Povalyaev N.M., Kotova E.O., Babukhina U.I., Koltsova E.M., Kobalava Z.D. Coagulation Disorders in Infective Endocarditis: Role of Pathogens, Biomarkers, Antithrombotic Therapy (Systematic Review). Rational Pharmacotherapy in Cardiology. 2022;18(3):320-331. https://doi.org/10.20996/1819-6446-2022-06-14

Views: 790


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)